Used in the treatment of hypercholesterolemia and prevention of cardiovascular diseases by targeting PCSK9, a protein that regulates LDL cholesterol levels in the blood. By inhibiting PCSK9, this antibody increases the liver’s ability to remove LDL cholesterol, significantly lowering circulating LDL levels. It is developed for patients with familial hypercholesterolemia or those who cannot achieve target cholesterol levels with statins alone. Administered via subcutaneous injection, it offers a long-acting option for chronic management of high cholesterol, reducing the risk of heart attack and stroke.